This may be useful for others, once the verdicts are in on this:
XL184 is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. MET is a receptor tyrosine kinase that plays key roles in cellular proliferation, migration, and invasion as well as angiogenesis1. These biological processes contribute to the transformation, progression, survival and metastasis of cancer cells1. The MET pathway is frequently activated in tumors through MET amplification, mutation, and overexpression, as well as through overexpression of its ligand HGF1. Expression of VEGF has been observed in a variety of cancers and has been associated with the stimulation and growth of new blood vessels to support the tumor2,3. MET and VEGFR2 are important driving forces in angiogenesis, implicated in the ability of tumors to overcome hypoxia following angiogenesis inhibition4,
Cut off the blood supply, new blood vessels and help halt the cancer, has been known about for years...hopefully this intervention shows usefulness. It appears they are entering Phase III soon and 'if' it gets beyond Phase III and into final phase...then it will become approved. Alot of drugs or protocols get killed in Phase II or Phase III...and not because the item is unuseful or whatever...it costs an absolute fortune to run these clinical Phase trials and some companies run out of money or resolve or other possible considerations (some might be less than righteous reasons, we have profits, lobbyist's and landslides of contributing factors)-FYI.